← Leaderboards
Gregory A Lizee
University Of Tx Md Anderson Can Ctr
$3,884,952
Attributed
$5,818,603
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $994.2K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,818,603 · 4
By mechanism
R01$4,251,087 · 2
U01$1,183,117 · 1
R21$384,399 · 1
Top collaborators
- Lydia E. Kavraki5 shared
- Patrick Hwu4 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Michael J Overman$2,432,364
- Laszlo George Radvanyi$2,629,361
- Michael Davies$11,575,720
- Cassian Yee$17,221,393
- Chantale Bernatchez$202,536
Others in their field
Top investigators on “Innovation”
- David R. Weir · University Of Michigan At Ann Arbor$382,307,654
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$319,874,172
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$311,654,401
- Richard A Gibbs · Baylor College Of Medicine$300,634,418
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$271,752,220
Research focus
InnovationCancer TherapyT-LymphocyteTumor AntigensTumorDesignPeptidesAntigensNeoplastic CellImmunotherapyCytotoxic T-LymphocytesImmuneCell SurfaceCancer PatientNext GenerationCancer ImmunotherapyLigandsComplexMalignant NeoplasmsMelanomaBaseSuccessCytotoxicMediating
Grant awards (14)
Identification and assessment of unconventional tumor-associated antigens as potential targets for cytotoxic T-cell based immunotherapy of cancer$581,244
R01 · FY2025 · CA · contact PI
Identification and assessment of unconventional tumor-associated antigens as potential targets for cytotoxic T-cell based immunotherapy of cancer$552,182
R01 · FY2024 · CA · contact PI
Identification and assessment of unconventional tumor-associated antigens as potential targets for cytotoxic T-cell based immunotherapy of cancer$569,619
R01 · FY2023 · CA · contact PI
PROTEAN-CR: Proteomics Toolkit for Ensemble Analysis in Cancer Research$383,598
U01 · FY2023 · CA
Identification and assessment of unconventional tumor-associated antigens as potential targets for cytotoxic T-cell based immunotherapy of cancer$596,742
R01 · FY2022 · CA · contact PI
PROTEAN-CR: Proteomics Toolkit for Ensemble Analysis in Cancer Research$397,442
U01 · FY2022 · CA
PROTEAN-CR: Proteomics Toolkit for Ensemble Analysis in Cancer Research$402,077
U01 · FY2021 · CA
Structure-based selection of tumor-antigens for T-cell based immunotherapy$202,434
R21 · FY2017 · CA
Structure-based selection of tumor-antigens for T-cell based immunotherapy$181,965
R21 · FY2016 · CA
Using the MHC class I cytoplasmic tail to control tumor Ag presentation by DCs$395,000
R01 · FY2015 · AI · contact PI
Using the MHC class I cytoplasmic tail to control tumor Ag presentation by DCs$395,000
R01 · FY2014 · AI · contact PI
Using the MHC class I cytoplasmic tail to control tumor Ag presentation by DCs$371,300
R01 · FY2013 · AI · contact PI
Using the MHC class I cytoplasmic tail to control tumor Ag presentation by DCs$395,000
R01 · FY2012 · AI · contact PI
Using the MHC class I cytoplasmic tail to control tumor Ag presentation by DCs$395,000
R01 · FY2011 · AI · contact PI